Dan Peer

Dan Peer, PhD

Full Affiliate Member, Research Institute
Houston Methodist


Publications

Therapeutic application of circular RNA aptamers in a mouse model of psoriasis
Guo, SK, Liu, CX, Xu, YF, Wang, X, Nan, F, Huang, Y, Li, S, Nan, S, Li, L, Kon, E, Li, C, Wei, MY, Su, R, Wei, J, Peng, S, Ad-El, N, Liu, J, Peer, D, Chen, T, Yang, L & Chen, LL 2024, , Nature Biotechnology. https://doi.org/10.1038/s41587-024-02204-4

Endosomal escape: A bottleneck for LNP-mediated therapeutics
Chatterjee, S, Kon, E, Sharma, P & Peer, D 2024, , Proceedings of the National Academy of Sciences of the United States of America, vol. 121, no. 11, e2307800120. https://doi.org/10.1073/pnas.2307800120

The immunostimulatory nature of mRNA lipid nanoparticles
Sharma, P, Hoorn, D, Aitha, A, Breier, D & Peer, D 2024, , Advanced Drug Delivery Reviews, vol. 205, 115175, pp. 115175. https://doi.org/10.1016/j.addr.2023.115175

Design of experiments in the optimization of nanoparticle-based drug delivery systems
Rampado, R & Peer, D 2023, , Journal of Controlled Release, vol. 358, pp. 398-419. https://doi.org/10.1016/j.jconrel.2023.05.001

Therapeutic gene silencing of CKAP5 leads to lethality in genetically unstable cancer cells
Chatterjee, S, Naidu, GS, Hazan-Halevy, I, Grobe, H, Ezra, A, Sharma, P, Goldsmith, M, Ramishetti, S, Sprinzak, D, Zaidel-Bar, R & Peer, D 2023, , Science advances, vol. 9, no. 14, eade4800, pp. eade4800. https://doi.org/10.1126/sciadv.ade4800

Drug-delivery research and much more: interview with Dan Peer
Peer, D 2023, , Nanomedicine, vol. 18, no. 8, pp. 649-652. https://doi.org/10.2217/nnm-2023-0121

A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium
Kon, E, Levy, Y, Elia, U, Cohen, H, Hazan-Halevy, I, Aftalion, M, Ezra, A, Bar-Haim, E, Naidu, GS, Diesendruck, Y, Rotem, S, Ad-El, N, Goldsmith, M, Mamroud, E, Peer, D & Cohen, O 2023, , Science advances, vol. 9, no. 10, eadg1036, pp. eadg1036. https://doi.org/10.1126/sciadv.adg1036

Genome editing in cancer: Challenges and potential opportunities
Breier, D & Peer, D 2023, , Bioactive Materials, vol. 21, pp. 394-402. https://doi.org/10.1016/j.bioactmat.2022.08.013

Targeted nanomedicine: Lessons learned and future directions
Veiga, N, Diesendruck, Y & Peer, D 2023, , Journal of Controlled Release, vol. 355, pp. 446-457. https://doi.org/10.1016/j.jconrel.2023.02.010

CRISPR editing in the lung with novel lipids
Elia, U, Kon, E & Peer, D 2023, , Nature Biotechnology, vol. 41, no. 10, pp. 1387-1388. https://doi.org/10.1038/s41587-023-01744-5

A Combinatorial Library of Lipid Nanoparticles for Cell Type-Specific mRNA Delivery
Naidu, GS, Yong, SB, Ramishetti, S, Rampado, R, Sharma, P, Ezra, A, Goldsmith, M, Hazan-Halevy, I, Chatterjee, S, Aitha, A & Peer, D 2023, , Advanced Science, vol. 10, no. 19, 2301929, pp. e2301929. https://doi.org/10.1002/advs.202301929

Delivery of Therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38-Targeted Lipid Nanoparticles
Tarab-Ravski, D, Hazan-Halevy, I, Goldsmith, M, Stotsky-Oterin, L, Breier, D, Naidu, GS, Aitha, A, Diesendruck, Y, Ng, BD, Barsheshet, H, Berger, T, Vaxman, I, Raanani, P & Peer, D 2023, , Advanced Science, vol. 10, no. 21, 2301377, pp. e2301377. https://doi.org/10.1002/advs.202301377

Lipid nanoparticles-loaded with toxin mRNA represents a new strategy for the treatment of solid tumors
Granot-Matok, Y, Ezra, A, Ramishetti, S, Sharma, P, Naidu, GS, Benhar, I & Peer, D 2023, , Theranostics, vol. 13, no. 11, pp. 3497-3508. https://doi.org/10.7150/thno.82228

Transport by circulating myeloid cells drives liposomal accumulation in inflamed synovium
Deprez, J, Verbeke, R, Meulewaeter, S, Aernout, I, Dewitte, H, Decruy, T, Coudenys, J, Van Duyse, J, Van Isterdael, G, Peer, D, van der Meel, R, De Smedt, SC, Jacques, P, Elewaut, D & Lentacker, I 2023, , Nature Nanotechnology, vol. 18, no. 11, pp. 1341-1350. https://doi.org/10.1038/s41565-023-01444-w

Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
Kon, E, Ad-El, N, Hazan-Halevy, I, Stotsky-Oterin, L & Peer, D 2023, , Nature Reviews Clinical Oncology, vol. 20, no. 11, pp. 739-754. https://doi.org/10.1038/s41571-023-00811-9

Cytotoxicity and reversal effect of sertraline, fluoxetine, and citalopram on MRP1- and MRP7-mediated MDR
Bin Kanner, Y, Teng, QX, Ganoth, A, Peer, D, Wang, JQ, Chen, ZS & Tsfadia, Y 2023, , Frontiers in Pharmacology, vol. 14, 1290255, pp. 1290255. https://doi.org/10.3389/fphar.2023.1290255

Identification of Cancer Cells in the Human Body by Anti-Telomerase Peptide Antibody: Towards the Isolation of Circulating Tumor Cells
Karpov, O, Lahav, M, Wolach, O, Raanani, P, Peer, D, Kaplan, T & Uziel, O 2022, , International journal of molecular sciences, vol. 23, no. 21, 12872. https://doi.org/10.3390/ijms232112872

A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs
Bogaert, B, Sauvage, F, Guagliardo, R, Muntean, C, Nguyen, VP, Pottie, E, Wels, M, Minnaert, AK, De Rycke, R, Yang, Q, Peer, D, Sanders, N, Remaut, K, Paulus, YM, Stove, C, De Smedt, SC & Raemdonck, K 2022, , Journal of Controlled Release, vol. 350, pp. 256-270. https://doi.org/10.1016/j.jconrel.2022.08.009

Principles for designing an optimal mRNA lipid nanoparticle vaccine
Kon, E, Elia, U & Peer, D 2022, , Current Opinion in Biotechnology, vol. 73, pp. 329-336. https://doi.org/10.1016/j.copbio.2021.09.016

Delivery strategies of RNA therapeutics to leukocytes
Tarab-Ravski, D, Stotsky-Oterin, L & Peer, D 2022, , Journal of Controlled Release, vol. 342, pp. 362-371. https://doi.org/10.1016/j.jconrel.2022.01.016